

Iovance Biotherapeutics

01:35 17 May 2019

Iovance Biotherapeutics stock flies on positive data for tumor-infiltrating lymphocyte technology

Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock soared Thursday after the late-stage biotechnology company shared positive interim data from clinical trials evaluating its novel cancer immunotherapy based on tumor-infiltrating lymphocyte (TIL) technology.

The new data will be presented at the annual meeting of the American Society of Clinical Oncology, in Chicago starting on May 31.

Investors cheered the news, sending shares in the company up nearly 33.9% to \$15.04.

READ: Hemispherx Biopharma's well-funded to take promising cancer drug Ampligen through clinical trials

In the early stages, the immune system tries to fight cancer by mobilizing special immune cells known as lymphocytes to attack the tumor, but cancer cells soon adapt and suppress the anti-tumor immune response. Iovance's TIL technology is designed to address the obstacles that block the natural anti-tumor immune response.

Encouraging data

Data from the innovaTIL-04 study, assessing lead candidate LN-145 in patients with a with recurrent, metastatic or persistent cervical cancer showed an objective response rate of 44% (1 complete response, 9 partial responses and 2 unconfirmed partial responses) and a disease control rate of 89%.

"As advanced cervical cancer is typically diagnosed at a relatively young age and efficacy of existing treatment options is extremely low, there is potential to significantly impact care with an option that can bring about long-term remission and complete responses," said study investigator Amir Jazaeri, who is associate professor of gynecological oncology and reproductive medicine at the MD Anderson Cancer Center. "The interim data from LN-145 present compelling evidence that TIL therapy, provided as a single administration, could improve upon current treatments."

On a separate note, updated results from Cohort 2 in the ongoing innovaTIL-01 study demonstrated a response rate 38% in 55 consecutively dosed post-PD-1 patients with Stage IIIC/IV melanoma, the most serious type of skin cancer.

"We are pleased to be sharing our broader melanoma data and now Gen-2 cervical data at ASCO. The data are indicative of the efficacy of TIL therapy in multiple indications," said Iovance Biotherapeutics CEO Maria Fardis. "We believe that TIL therapy is a platform which may offer patients with different advanced cancers a potential therapy."

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Price: \$20.94

Market Cap: \$2.59 billion

1 Year Share Price Graph



September 2018 March 2019 September 2019

Share Information

Code: IOVA

Listing: NASDAQ

52 week	High	Low
	26.55	7.27

Sector: Pharma & Biotech

Website: www.iovance.com

Company Synopsis:

IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL).

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.